MedTrace Logo

Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus

NCT02097342 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-04-08

No results posted yet for this study

Summary

This study is planned to evaluate if linagliptin can improve insulin sensitivity in patients with type 2 diabetes mellitus. In addition, the effect of linagliptin on pancreatic function will be studied.

Conditions

Interventions

DRUG

Linagliptin

Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months

DRUG

Placebo

Tablet placebo per oral, once daily will be given to 10 patients for 6 months

DRUG

Voglibose

Tablet Voglibose (0.2mg) per oral thrice daily(with meals) to 10 patients for 6 months

Sponsors & Collaborators

  • Post Graduate Institute of Medical Education and Research, Chandigarh

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-11-30
Completion
2015-01-31

Countries

  • India

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02097342 on ClinicalTrials.gov